Arrowhead Research Corporation (ARWR)

Oncology Corporate Profile

Stock Performance

1.8900
0.0000

HQ Location

225 South Lake Avenue, 3rd Floor
Pasadena, 91101

Company Description

Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. The Company has clinical programs in small RNA therapeutics and obesity. Arrowhead's programs are based on its proprietary drug development and delivery platforms, each capable of creating multiple therapeutic products. This strategy seeks to enhance the return potential for investors and reduce risk compared to traditional biotech companies. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to optimize therapeutic agents for a wide range of diseases.

Website: http://www.arrowheadresearch.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cyclosert / CRLX-101topoisomerase I inhibitorNon Small Cell Lung Cancer (NSCLC)IICerulean Pharma, Inc.
CALAA-01RNAi therapeuticVarious cancer typesICalando Pharmaceuticals
cyclosert / CRLX-101topoisomerase I inhibitorVarious cancer typesPreclinicalTube Pharma
UnnamedRNA antagonist (HIF-1 alpha antagonist)Various cancer typesResearch

View additional information on product candidates here »

Source


http://www.arrowheadresearch.com/

Recent News Headlines

Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

3/23/2017 11:03 am

[Business Wire] - Arrowhead Pharmaceuticals Inc. today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share purchase right on each outstanding share of the company’s common stock.

Arrowhead Reports Fiscal 2017 First Quarter Results

2/6/2017 09:00 pm

[Business Wire] - Arrowhead Pharmaceuticals, Inc. today announced financial results for its fiscal 2017 first quarter ended December 31, 2016. The company is hosting a conference call at 4:30 p.m.

Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health

2/1/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2017 / The Biotech Industry has outperformed the broader markets in 2017, despite all the criticism drug makers have been facing. The iShares NASDAQ Biotechnology ...

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results

1/30/2017 09:00 pm

[Business Wire] - Arrowhead Pharmaceuticals, Inc. today announced that it will host a webcast and conference call on Monday, February 6, 2017, at 4:30 p.m. EST to discuss its financial results for the fiscal 2017 first quarter ended December 31, 2016.

Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action

1/21/2017 12:05 am

[Business Wire] - Shareholder rights law firm, Robbins Arroyo LLP, announces that a class action complaint was filed against Arrowhead Pharmaceuticals, Inc. in the U.S.

IMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

1/14/2017 11:02 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / January 14, 2017 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") ...

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers – ARWR

1/13/2017 10:04 pm

[GlobeNewswire] - NEW YORK, Jan. 13, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Arrowhead Pharmaceuticals, Inc. and certain of its officers. The class action, filed in the United States ...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR

1/13/2017 04:00 pm

[GlobeNewswire] - NEW YORK, Jan. 13, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc. ...

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

1/12/2017 04:00 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / January 12, 2017 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") ...

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017

1/12/2017 03:01 pm

[GlobeNewswire] - NEW YORK, Jan. 12, 2017-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Arrowhead Pharmaceuticals, Inc. and certain of its ...

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

1/10/2017 03:05 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / January 10, 2017 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") ...